Retatrutide and blood pressure — 6 month update

EndoResFellow said:

Dr.SurgeonPGH said: ...we don't know the long-term effects of cardiovascular risk...

I'm 67 years old and want to share my perspective on cardiovascular risk as an older member of this community.

My doctor was initially hesitant because of my age, but the SELECT trial included patients up to 72 and showed consistent benefit across age groups. We started at the lowest dose with closer monitoring.

12 months later: down 49 lbs, off atorvastatin, A1C from 7.8% to 5.2%. My cardiologist is thrilled. cardiovascular risk is absolutely relevant for older adults — don't let anyone tell you otherwise.

RegAffairsDC said:

Fair, but phase 2 tolerability figures rarely survive contact with phase 3 scale.

Genuinely useful, thank you. I had the facts and not the framework. Sending this to two other people who asked me the same thing last week.

EndoResFellow said:

Dr.SurgeonPGH said: ...we don't know the long-term effects of cardiovascular risk...

I would rather people stopped quoting the 24% as if it were a licensed outcome. It is a phase 2 result in a few hundred participants with no cardiovascular endpoint and no long-term safety data, and this board has a habit of treating pipeline numbers as settled.

Ask again with the specifics and you will get a better answer than this one.

SleepDoc_PDX said:

My reason for being on this is cardiovascular rather than cosmetic, which puts me in a small minority in most of these threads.

SUSTAIN-6 was the first CVOT to show cardiovascular benefit with semaglutide, relevant to cardiovascular risk. In 3,297 T2DM patients with high CV risk: MACE HR 0.74 (95% CI 0.58-0.95, p=0.02)[1].

Notable: the retinopathy signal in SUSTAIN-6 (HR 1.76) was subsequently attributed to rapid A1C reduction in patients with pre-existing retinopathy — not a direct drug effect. This has been confirmed in longer-term follow-up studies.

Moderator note: reminder that nothing in this thread is medical advice, and that clinical claims need a source.